TNDM Stock Forecast & Price Target

Tandem Diabetes Care is attractive because its underlying pump demand remains healthy, with record shipments of 22K, new starts rising 20%+ sequentially, and MDI conversions growing mid-single digits, while nearly 3/4 of revenue still comes from the U.S. and recurring supplies already make up about one-third of sales. Its PayGo and pharmacy-channel shift is lifting supply ASPs and improving lifetime revenue per patient, with 10% of U.S. sales already flowing through pharmacy and formulary coverage at 45%, even as the temporary pump headwind is more than offset by pricing benefits. Long-term upside also comes from a broad innovation pipeline—Mobi, Mobi Tubeless, Sigi, extended-wear sets, and Control-IQ enhancements—supporting an underpenetrated 11MM-patient market and a path to stronger margins and accelerating growth.

Tandem Diabetes Care is viewed negatively because it operates in a highly competitive diabetes-device market where rapid change, pricing pressure, and reimbursement uncertainty can constrain growth and margins. Revenue of $247M in the period cited, with US sales of $161M and OUS sales of $86M, was aided by pump shipments but still faced supplier shortages in infusion sets, while new patient starts slipped and renewals remained more than half of pump shipments. The company’s reliance on insulin delivery systems, possible GLP-1 substitution risk, execution risk around pharmacy-channel conversion, and ongoing difficulty achieving consistent profitability make its longer-term fundamental profile fragile.